A Two-site, Phase 1, Partially-blinded, Placebo-controlled Safety, Acceptability and Pharmacokinetic Trial of Topical, Vaginally-formulated Tenofovir 1% Gel Applied Rectally Compared With Oral 300 mg Tenofovir Disoproxil Fumarate in HIV-1 Seronegative Adults.

Trial Profile

A Two-site, Phase 1, Partially-blinded, Placebo-controlled Safety, Acceptability and Pharmacokinetic Trial of Topical, Vaginally-formulated Tenofovir 1% Gel Applied Rectally Compared With Oral 300 mg Tenofovir Disoproxil Fumarate in HIV-1 Seronegative Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2012

At a glance

  • Drugs Tenofovir (Primary) ; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors CONRAD
  • Most Recent Events

    • 02 Mar 2011 Results presented at the 18th Conference on Retroviruses and Opportunistic Infections.
    • 01 Nov 2010 Status changed from recruiting to completed.
    • 02 Oct 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top